盐酸曲唑酮缓释剂临床应用专家建议

2022-08-28 上海市精神卫生中心 中国全科医学

盐酸曲唑酮缓释剂作为一种多受体结合药物,不同剂量可发挥不同的药理作用、改善多种精神障碍。为进一步规范盐酸曲唑酮缓释剂的临床应用,本专家撰写组整合了国内外临床试验、临床实践指南、处方指南及临床用药经验,

中文标题:

盐酸曲唑酮缓释剂临床应用专家建议

发布机构:

上海市精神卫生中心

发布日期:

2022-08-28

简要介绍:

盐酸曲唑酮缓释剂作为一种多受体结合药物,不同剂量可发挥不同的药理作用、改善多种精神障碍。为进一步规范盐酸曲唑酮缓释剂的临床应用,本专家撰写组整合了国内外临床试验、临床实践指南、处方指南及临床用药经验,撰写了此临床应用专家建议。本文提到盐酸曲唑酮缓释剂在临床上适用于抑郁症、各种原因引起的失眠,还应用于广泛性焦虑障碍、性功能障碍、创伤后应激障碍、物质依赖和戒断反应及强迫障碍,并说明了药物用法用量、相互作用,以及特殊人群使用的注意事项,以期为临床医生提供科学、全面的用药指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=盐酸曲唑酮缓释剂临床应用专家建议_潘集阳.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a33ac1c00263013d, title=盐酸曲唑酮缓释剂临床应用专家建议, enTitle=, guiderFrom=中国全科医学, authorId=0, author=, summary=盐酸曲唑酮缓释剂作为一种多受体结合药物,不同剂量可发挥不同的药理作用、改善多种精神障碍。为进一步规范盐酸曲唑酮缓释剂的临床应用,本专家撰写组整合了国内外临床试验、临床实践指南、处方指南及临床用药经验,, cover=https://img.medsci.cn/Random/confident-experienced-doctor-NJVKHS4.jpg, journalId=0, articlesId=null, associationId=3142, associationName=上海市精神卫生中心, associationIntro=上海市精神卫生中心, copyright=0, guiderPublishedTime=Sun Aug 28 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">盐酸曲唑酮缓释剂作为一种多受体结合药物,不同剂量可发挥不同的药理作用、改善多种精神障碍。为进一步规范盐酸曲唑酮缓释剂的临床应用,本专家撰写组整合了国内外临床试验、临床实践指南、处方指南及临床用药经验,撰写了此临床应用专家建议。本文提到盐酸曲唑酮缓释剂在临床上适用于抑郁症、各种原因引起的失眠,还应用于广泛性焦虑障碍、性功能障碍、创伤后应激障碍、物质依赖和戒断反应及强迫障碍,并说明了药物用法用量、相互作用,以及特殊人群使用的注意事项,以期为临床医生提供科学、全面的用药指导。</span></p>, tagList=[TagDto(tagId=20217, tagName=中国专家建议), TagDto(tagId=460208, tagName=盐酸曲唑酮)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=59114, articleKeyword=精神心理疾病, articleKeywordNum=6, guiderKeywordId=116, guiderKeyword=精神科, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2227, appHits=105, showAppHits=0, pcHits=544, showPcHits=2121, likes=2, shares=19, comments=4, approvalStatus=1, publishedTime=Tue Aug 30 10:09:00 CST 2022, publishedTimeString=2022-08-28, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=7, createdBy=null, createdName=lixiang, createdTime=Sun Aug 28 22:09:30 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 10:15:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=盐酸曲唑酮缓释剂临床应用专家建议_潘集阳.pdf)])
盐酸曲唑酮缓释剂临床应用专家建议_潘集阳.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1243049, encodeId=924d124304975, content=很实用很精细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70798259957, createdName=ms5000002050940359, createdTime=Sat Sep 03 23:42:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242035, encodeId=408612420355b, content=为合理应用抗抑郁药提供了参考,很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Tue Aug 30 11:34:16 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242176, encodeId=a07812421e64a, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:51 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242175, encodeId=53be12421e5f7, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:16 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-09-03 ms5000002050940359

    很实用很精细

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1243049, encodeId=924d124304975, content=很实用很精细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70798259957, createdName=ms5000002050940359, createdTime=Sat Sep 03 23:42:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242035, encodeId=408612420355b, content=为合理应用抗抑郁药提供了参考,很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Tue Aug 30 11:34:16 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242176, encodeId=a07812421e64a, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:51 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242175, encodeId=53be12421e5f7, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:16 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-08-30 146480bem82暂无昵称

    为合理应用抗抑郁药提供了参考,很棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1243049, encodeId=924d124304975, content=很实用很精细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70798259957, createdName=ms5000002050940359, createdTime=Sat Sep 03 23:42:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242035, encodeId=408612420355b, content=为合理应用抗抑郁药提供了参考,很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Tue Aug 30 11:34:16 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242176, encodeId=a07812421e64a, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:51 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242175, encodeId=53be12421e5f7, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:16 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-08-30 ms4000000271054812

    写得好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1243049, encodeId=924d124304975, content=很实用很精细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70798259957, createdName=ms5000002050940359, createdTime=Sat Sep 03 23:42:07 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242035, encodeId=408612420355b, content=为合理应用抗抑郁药提供了参考,很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05155126416, createdName=146480bem82暂无昵称, createdTime=Tue Aug 30 11:34:16 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242176, encodeId=a07812421e64a, content=写得好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:51 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242175, encodeId=53be12421e5f7, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c648300402, createdName=ms4000000271054812, createdTime=Tue Aug 30 22:50:16 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-08-30 ms4000000271054812

    不错

    0

拓展阅读

Schizophrenia Bulletin:自残住院的青少年未来患精神心理疾病风险高

在医院就诊的青少年自残是晚期精神病和双相情感障碍的一个强烈的风险标志。自残入院的年轻人未来患精神病和躁郁症的风险很高。他们是预防严重精神疾病的重要群体。

JAMA Pediatr:青少年服用阿片类药物导致精神心理疾病风险增加

研究认为,青少年阿片类长期服用率较低,但阿片类暴露与青少年精神心理障碍之间的相关性却十分显著

Headache: 综述:偏头痛与常见精神心理共病

偏头痛是一种常见的、可能会使人衰弱的慢性神经系统疾病,常常伴随常见的精神疾病。偏头痛对个人和社会影响较为显着,且具有多样性,这些影响也包括多种精神疾病。

2016 WFSBP专家共识:精神科患者激越的评估和管理

世界生物精神病学会联合会(WFSBP,World Federation of Societies of Biological Psychiatry) · 2016-03-01

2015 美国精神病学会实践指南:成人精神科评估要点(翻译版)

美国精神病学会(APA,American Psychiatric Association) · 2015-10-27